dwb2023/gtopdb-target-family-interaction-detail huggingface dataset:
Target family: MAPKAPK subfamily (type: enzyme)
Target: MAPK activated protein kinase 5

Ligand: compound 16 [PMID: 17480064] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.090000152587891 pIC50
Reference (Journal): Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2).
Published in: J Med Chem

Ligand: compound 16 [PMID: 18945615] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.619999885559082 pIC50
Reference (Journal): Pyrrolo-pyrimidones: a novel class of MK2 inhibitors with potent cellular activity.
Published in: Bioorg Med Chem Lett

Ligand: Galapagos MAPKAPK5 inhibitor D (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Patent): Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases

Ligand: Galapagos MAPKAPK5 inhibitor D (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.429999828338623 pIC50
Reference (Webpage): Discovery of inhibitors of MAPKAPK5, a novel target for rheumatoid arthritis
Target family: MARK subfamily (type: enzyme)
Target: microtubule affinity regulating kinase 2

Ligand: PCC0105003 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.699999809265137 pIC50
Reference (Journal): A novel role for microtubule affinity-regulating kinases in neuropathic pain.
Published in: Br J Pharmacol
Target family: MARK subfamily (type: enzyme)
Target: microtubule affinity regulating kinase 1

Ligand: 7-hydroxystaurosporine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.570000171661377 pIC50
Reference (Journal): The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1.
Published in: Cancer Res

Ligand: PCC0105003 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.520000457763672 pIC50
Reference (Journal): A novel role for microtubule affinity-regulating kinases in neuropathic pain.
Published in: Br J Pharmacol
Target family: MARK subfamily (type: enzyme)
Target: microtubule affinity regulating kinase 4

Ligand: PCC0208017 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.699999809265137 pIC50
Reference (Journal): PCC0208017, a novel small-molecule inhibitor of MARK3/MARK4, suppresses glioma progression <i>in&#xa0;vitro</i> and <i>in&#xa0;vivo</i>.
Published in: Acta Pharm Sin B

Ligand: PCC0105003 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.569999694824219 pIC50
Reference (Journal): A novel role for microtubule affinity-regulating kinases in neuropathic pain.
Published in: Br J Pharmacol

Ligand: compound 14 [PMID: 34333981] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.090000152587891 pIC50
Reference (Journal): Identification of Pyrimidine-Based Lead Compounds for Understudied Kinases Implicated in Driving Neurodegeneration.
Published in: J Med Chem
Target family: MARK subfamily (type: enzyme)
Target: microtubule affinity regulating kinase 3

Ligand: PCC0208017 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.739999771118164 pIC50
Reference (Journal): PCC0208017, a novel small-molecule inhibitor of MARK3/MARK4, suppresses glioma progression <i>in&#xa0;vitro</i> and <i>in&#xa0;vivo</i>.
Published in: Acta Pharm Sin B

Ligand: PCC0105003 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.569999694824219 pIC50
Reference (Journal): A novel role for microtubule affinity-regulating kinases in neuropathic pain.
Published in: Br J Pharmacol

Ligand: compound 17d [PMID: 23099093] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.920000076293945 pIC50
Reference (Journal): Synthesis and structure-activity relationships of a novel series of pyrimidines as potent inhibitors of TBK1/IKKε kinases.
Published in: Bioorg Med Chem Lett

Ligand: compound 14 [PMID: 34333981] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.400000095367432 pIC50
Reference (Journal): Identification of Pyrimidine-Based Lead Compounds for Understudied Kinases Implicated in Driving Neurodegeneration.
Published in: J Med Chem
Target family: MAST family (type: enzyme)
Target: Microtubule associated serine/threonine kinase 3

Ligand: compound 35 [PMID: 23916259] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.619999885559082 pIC50
Reference (Journal): Hit-to-lead optimization and kinase selectivity of imidazo[1,2-a]quinoxalin-4-amine derived JNK1 inhibitors.
Published in: Bioorg Med Chem Lett
Target family: Maxi chloride channel (type: other_ic)
Target: Maxi Cl<sup>-</sup>

Ligand: arachidonic acid (Metabolite)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity:  -

Ligand: Zn2+ (Inorganic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity: 4.3 pIC50
Reference (Journal): Insights into the ClC-4 transport mechanism from studies of Zn2+ inhibition.
Published in: Biophys J

Ligand: GTPγS (Synthetic organic)
Interaction type: Activator
Action: None
Median affinity:  -

Ligand: DIDS (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity: 4.4 pIC50
Reference (Journal): The G215R mutation in the Cl-/H+-antiporter ClC-7 found in ADO II osteopetrosis does not abolish function but causes a severe trafficking defect.
Published in: PLoS ONE

Ligand: diphenylamine-2-carboxylic acid (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity:  -

Ligand: triflupromazine (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: yes
Approval source: FDA (1957)
Median affinity:  -

Ligand: toremifene (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: yes
Approval source: EMA (1996), FDA (1997)
Median affinity:  -

Ligand: Gd3+ (Inorganic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity:  -

Ligand: NPPB (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity: 3.8 pIC50
Reference (Journal): The G215R mutation in the Cl-/H+-antiporter ClC-7 found in ADO II osteopetrosis does not abolish function but causes a severe trafficking defect.
Published in: PLoS ONE

Ligand: tamoxifen (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: yes
Approval source: FDA (1977)
Median affinity:  -

Ligand: SITS (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity:  -

Ligand: chlorpromazine (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: yes
Approval source: FDA (1957)
Median affinity:  -
Target family: Melanin-concentrating hormone receptors (type: gpcr)
Target: MCH<sub>2</sub> receptor

Ligand: Ac-hMCH-(6-16)-NH2 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Synthesis and biological evaluation in vitro of selective, high affinity peptide antagonists of human melanin-concentrating hormone action at human melanin-concentrating hormone receptor 1.
Published in: Biochemistry

Ligand: ATC0065 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Anxiolytic- and antidepressant-like profile of ATC0065 and ATC0175: nonpeptidic and orally active melanin-concentrating hormone receptor 1 antagonists.
Published in: J Pharmacol Exp Ther

Ligand: [Ava9,10,Ava14,15]-Ac-hMCH6-16-NH2 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 7.3 pIC50
Reference (Journal): Synthesis and biological evaluation in vitro of selective, high affinity peptide antagonists of human melanin-concentrating hormone action at human melanin-concentrating hormone receptor 1.
Published in: Biochemistry

Ligand: compound 38 [PMID: 22123324] (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: yes
Median affinity: 9 pIC50
Reference (Journal): Discovery and characterization of a potent and selective antagonist of melanin-concentrating hormone receptor 2.
Published in: Bioorg Med Chem Lett

Ligand: MCH (salmon) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Identification and characterization of a second melanin-concentrating hormone receptor, MCH-2R.
Published in: Proc Natl Acad Sci USA

Ligand: MCH (salmon) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Identification and pharmacological characterization of a novel human melanin-concentrating hormone receptor, mch-r2.
Published in: J Biol Chem

Ligand: melanin-concentrating hormone (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Identification and characterization of a second melanin-concentrating hormone receptor, MCH-2R.
Published in: Proc Natl Acad Sci USA

Ligand: [Phe13,Tyr19]MCH (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Identification and characterization of a second melanin-concentrating hormone receptor, MCH-2R.
Published in: Proc Natl Acad Sci USA

Ligand: [Phe13,Tyr19]MCH (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Identification and pharmacological characterization of a novel human melanin-concentrating hormone receptor, mch-r2.
Published in: J Biol Chem
Target family: Melanocortin receptors (type: gpcr)
Target: MC<sub>3</sub> receptor

Ligand: α-MSH (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Characterization of melanocortin receptor ligands on cloned brain melanocortin receptors and on grooming behavior in the rat.
Published in: Eur J Pharmacol

Ligand: agouti-related protein (Peptide)
Interaction type: Antagonist
Action: Inverse agonist
Ligand approved: no
Median affinity: 7.7 pIC50
Reference (Journal): Biochemical, biophysical, and pharmacological characterization of bacterially expressed human agouti-related protein.
Published in: Biochemistry

Ligand: agouti (Peptide)
Interaction type: Antagonist
Action: Inverse agonist
Ligand approved: no
Median affinity: 6.7 pIC50
Reference (Journal): Melanocortin receptor binding determinants in the agouti protein.
Published in: Biochemistry

Ligand: afamelanotide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: EMA (2014), FDA (2019)
Median affinity: 8.9 pKi
Reference (Journal): Characterization of melanocortin receptor ligands on cloned brain melanocortin receptors and on grooming behavior in the rat.
Published in: Eur J Pharmacol

Ligand: ACTH (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1950)
Primary target: no
Median affinity: 7.059999942779541 pKi
Reference (Journal): Characterisation of melanocortin receptor subtypes by radioligand binding analysis.
Published in: Eur J Pharmacol
Target family: Melanocortin receptors (type: gpcr)
Target: MC<sub>2</sub> receptor

Ligand: [125I]ACTH-(1-24) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: CRN04894 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.470000267028809 pKB
Reference (Journal): Discovery of CRN04894: A Novel Potent Selective MC2R Antagonist.
Published in: ACS Med Chem Lett

Ligand: CRN04894 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.640000343322754 pKB
Reference (Journal): Discovery of CRN04894: A Novel Potent Selective MC2R Antagonist.
Published in: ACS Med Chem Lett

Ligand: cosyntropin (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1970)
Primary target: yes
Median affinity:  -

Ligand: corticotropin zinc hydroxide (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1955)
Primary target: yes
Median affinity:  -

Ligand: corticotrophin-releasing hormone (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: yes
Median affinity:  -

Ligand: ASIP [90-132 (L89Y)] (Peptide)
Interaction type: Antagonist
Action: Inverse agonist
Ligand approved: no
Median affinity: 7.3 pIC50
Reference (Journal): Functional properties of an agouti signaling protein variant and characteristics of its cognate radioligand.
Published in: Am J Physiol Regul Integr Comp Physiol

Ligand: ACTH-(1-24) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 9.1 pKd
Reference (Journal): Agonist and receptor binding properties of adrenocorticotropin peptides using the cloned mouse adrenocorticotropin receptor expressed in a stably transfected HeLa cell line.
Published in: Endocrinology

Ligand: ACTH-(11-24) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 9 pKd
Reference (Journal): Agonist and receptor binding properties of adrenocorticotropin peptides using the cloned mouse adrenocorticotropin receptor expressed in a stably transfected HeLa cell line.
Published in: Endocrinology

Ligand: ACTH (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 9.8 pKd
Reference (Journal): Agonist and receptor binding properties of adrenocorticotropin peptides using the cloned mouse adrenocorticotropin receptor expressed in a stably transfected HeLa cell line.
Published in: Endocrinology
Target family: Melatonin receptors (type: gpcr)
Target: MT<sub>2</sub> receptor

Ligand: 6-Cl-MLT (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Melatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor.
Published in: Naunyn Schmiedebergs Arch Pharmacol
Target family: MELK subfamily (type: enzyme)
Target: maternal embryonic leucine zipper kinase

Ligand: MELK-TI (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.639999866485596 pIC50
Reference (Journal): Fragment-based discovery of type I inhibitors of maternal embryonic leucine zipper kinase.
Published in: ACS Med Chem Lett

Ligand: CC-401 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.46999979019165 pIC50
Reference (Journal): Discovery of a potent inhibitor of MELK that inhibits expression of the anti-apoptotic protein Mcl-1 and TNBC cell growth.
Published in: Bioorg Med Chem

Ligand: OTSSP167 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.390000343322754 pIC50
Reference (Journal): Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer.
Published in: Oncotarget
Target family: Membrane bound O-acyltransferases (type: enzyme)
Target: porcupine O-acyltransferase

Ligand: GNF-1331 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.100000381469727 pIC50
Reference (Journal): Discovery of Pyridinyl Acetamide Derivatives as Potent, Selective, and Orally Bioavailable Porcupine Inhibitors.
Published in: ACS Med Chem Lett

Ligand: GNF-6231 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.100000381469727 pIC50
Reference (Journal): Discovery of Pyridinyl Acetamide Derivatives as Potent, Selective, and Orally Bioavailable Porcupine Inhibitors.
Published in: ACS Med Chem Lett

Ligand: LGK974 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9 pIC50
Reference (Journal): Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974.
Published in: Proc Natl Acad Sci USA

Ligand: Wnt-C59 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 10.130000114440918 pIC50
Reference (Journal): The use of porcupine inhibitors to target Wnt-driven cancers.
Published in: Bioorg Med Chem Lett

Ligand: ETC-1922159 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.539999961853027 pIC50
Reference (Journal): The use of porcupine inhibitors to target Wnt-driven cancers.
Published in: Bioorg Med Chem Lett
Target family: Metabotropic glutamate receptors (type: gpcr)
Target: mGlu<sub>6</sub> receptor

Ligand: LSP4-2022 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 5.36 pEC50
Reference (Journal): A novel selective metabotropic glutamate receptor 4 agonist reveals new possibilities for developing subtype selective ligands with therapeutic potential.
Published in: FASEB J

Ligand: LY379268 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.4 pIC50
Reference (Journal): Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors.
Published in: J Med Chem

Ligand: MAP4 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 3.5 pIC50
Reference (Journal): The metabotropic glutamate receptors: structure, activation mechanism and pharmacology.
Published in: Curr Drug Targets CNS Neurol Disord

Ligand: MPPG (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 3.3 pIC50
Reference (Journal): Synthesis and biological acitivity of cyclic analogues of MPPG and MCPG as metabotropic glutamate receptor antagonists.
Published in: Bioorg Med Chem Lett

Ligand: PHCCC (Synthetic organic)
Interaction type: Allosteric modulator
Action: Positive
Ligand approved: no
Median affinity: 4.8 pEC50
Reference (Journal): The mGlu(4) receptor allosteric modulator N-phenyl-7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide acts as a direct agonist at mGlu(6) receptors.
Published in: Eur J Pharmacol

Ligand: [3H]LY341495 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 4.5 pEC50
Reference (Journal): Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: THPG (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Median affinity:  -
Reference (Journal): Two phenylglycine derivatives antagonize responses to L-AP4 in ON bipolar cells of the amphibian retina.
Published in: Neuropharmacology
Target family: Metabotropic glutamate receptors (type: gpcr)
Target: mGlu<sub>4</sub> receptor

Ligand: [3H]AP4 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.3 pKd
Reference (Journal): Ligand binding to the amino-terminal domain of the mGluR4 subtype of metabotropic glutamate receptor.
Published in: J Biol Chem
Target family: Metal-dependent protein phosphatase (PPM) family (type: enzyme)
Target: protein phosphatase, Mg2+/Mn2+ dependent 1D

Ligand: GSK2830371 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.889999866485596 pIC50
Reference (Journal): Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction.
Published in: Nat Chem Biol

Ligand: SL-176 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.960000038146973 pIC50
Reference (Journal): Novel inhibitors targeting PPM1D phosphatase potently suppress cancer cell proliferation.
Published in: Bioorg Med Chem

Ligand: GSK2830371 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.070000171661377 pIC50
Reference (Journal): Novel inhibitors targeting PPM1D phosphatase potently suppress cancer cell proliferation.
Published in: Bioorg Med Chem
Target family: Meta subfamily (type: enzyme)
Target: calcium/calmodulin dependent protein kinase kinase 2

Ligand: STO609 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.400000095367432 pIC50
Reference (Journal): STO-609, a specific inhibitor of the Ca(2+)/calmodulin-dependent protein kinase kinase.
Published in: J Biol Chem
Target family: Meta subfamily (type: enzyme)
Target: calcium/calmodulin dependent protein kinase kinase 1

Ligand: STO609 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 6.849999904632568 pIC50
Reference (Journal): STO-609, a specific inhibitor of the Ca(2+)/calmodulin-dependent protein kinase kinase.
Published in: J Biol Chem
Target family: Methyllysine reader proteins (type: other_protein)
Target: spindlin 1

Ligand: MS8535 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.519999980926514 pKd
Reference (Journal): Discovery of a Potent, Selective, and Cell-Active SPIN1 Inhibitor.
Published in: J Med Chem

Ligand: MS31 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.039999961853027 pKd

Ligand: MS31 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.110000133514404 pIC50
Reference (Journal): Discovery of a Potent and Selective Fragment-like Inhibitor of Methyllysine Reader Protein Spindlin 1 (SPIN1).
Published in: J Med Chem
Target family: Methyllysine reader proteins (type: other_protein)
Target: L3MBTL histone methyl-lysine binding protein 3

Ligand: UNC1215 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: yes
Median affinity: 6.920000076293945 pKd
Reference (Journal): Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain.
Published in: Nat Chem Biol
Target family: Methyllysine reader proteins (type: other_protein)
Target: spindlin 1

Ligand: MS8535 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.690000057220459 pIC50
Reference (Journal): Discovery of a Potent, Selective, and Cell-Active SPIN1 Inhibitor.
Published in: J Med Chem